Company news
Lixte Biotechnology Holdings, Inc. news in 2022
Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2022, newest first.
LIXTE Biotechnology announces approval of a Phase 1B/2 randomized trial of doxorubicin +/-LB-100 in advanced soft tissue sarcomas to be conducted by the Spanish Sarcoma Group
October 12, 2022
LIXTE Biotechnology announces appointment of bas van der Baan, internationally recognized biotech business development executive, to its board of directors
June 20, 2022
LIXTE Biotechnology announces appointment of Professor René Bernards to its board of directors
June 14, 2022
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
April 11, 2022
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
April 11, 2022
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
January 11, 2022
Decks in 2022
- Investor Presentation (December 2022)
Investor deck · 20 slides · Dec 6, 2022